Infusion-Compatible Antibiotic Formulations for Rapid Administration to Improve Outcomes in Cancer Outpatients With Severe Sepsis and Septic Shock: The Sepsis STAT Pack

Overview

Journal J Natl Compr Canc Netw

Specialty Oncology

Date 2017 Apr 14

PMID 28404756

Citations 1

Authors

Jason D Goldman

Amelia Gallaher

Rupali Jain

Zach Stednick

Manoj Menon

Michael J Boeckh

Paul S Pottinger

Stephen M Schwartz

Corey Casper

Affiliations

Soon will be listed here.

Abstract

Patients with cancer are at high risk for severe sepsis and septic shock (SS/SSh), and a delay in receiving effective antibiotics is strongly associated with mortality. Delays are due to logistics of clinic flow and drug delivery. In an era of increasing antimicrobial resistance, combination therapy may be superior to monotherapy for patients with SS/SSh. At the Seattle Cancer Care Alliance, we implemented the Sepsis STAT Pack (SSP) program to simplify timely and effective provision of empiric antibiotics and other resuscitative care to outpatients with cancer with suspected SS/SSh before hospitalization. Over a 49-month period from January 1, 2008, through January 31, 2012, a total of 162 outpatients with cancer received the intervention. A retrospective cohort study was conducted to determine outcomes, including mortality and adverse events associated with the use of a novel care bundle designed for compatibility of broad-spectrum antibiotics and other supportive care administered concurrently via rapid infusion at fixed doses. Of 162 sequential patients with cancer and suspected SS/SSh who received the SSP, 71 (44%) were diagnosed with SS/SSh. Median age was 53 years and 65% were men; 141 (87%) had hematologic malignancies, 77 (48%) were transplant recipients, and 80 (49%) were neutropenic. Median time to completion of antibiotics was 111 minutes (interquartile range, 60-178 minutes). A total of 71 patients (44%) had bacteremia and 17% of 93 isolates were multidrug-resistant. Possibly related nephrotoxicity occurred in 7 patients, and 30-day mortality occured in 6 of 160 patients (4%), including 3 of 71 (4%) with SS/SSh. Risk of developing SSh or death within 30 days increased 18% (95% CI, 4%-34%) for each hour delay to completion of antibiotics (=.01). Rapidly administered combination antibiotics and supportive care delivered emergently to ambulatory patients with cancer with suspected SS/SSh was well-tolerated and associated with excellent short-term survival.

Citing Articles

Gut Microbiota and Tumor Immune Escape: A New Perspective for Improving Tumor Immunotherapy.

He Y, Huang J, Li Q, Xia W, Zhang C, Liu Z Cancers (Basel). 2022; 14(21).

PMID: 36358736 PMC: 9656981. DOI: 10.3390/cancers14215317.

References

Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B . Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2002; 345(19):1368-77. DOI: 10.1056/NEJMoa010307. View

Larche J, Azoulay E, Fieux F, Mesnard L, Moreau D, Thiery G . Improved survival of critically ill cancer patients with septic shock. Intensive Care Med. 2003; 29(10):1688-95. DOI: 10.1007/s00134-003-1957-y. View

Williams M, Braun L, Cooper L, Johnston J, Weiss R, Qualy R . Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care. Crit Care. 2004; 8(5):R291-8. PMC: 1065011. DOI: 10.1186/cc2893. View

Paul M, Silbiger I, Grozinsky S, Soares-Weiser K, Leibovici L . Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev. 2006; (1):CD003344. DOI: 10.1002/14651858.CD003344.pub2. View

Kumar A, Roberts D, Wood K, Light B, Parrillo J, Sharma S . Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006; 34(6):1589-96. DOI: 10.1097/01.CCM.0000217961.75225.E9. View

Pene F, Percheron S, Lemiale V, Viallon V, Claessens Y, Marque S . Temporal changes in management and outcome of septic shock in patients with malignancies in the intensive care unit. Crit Care Med. 2008; 36(3):690-6. DOI: 10.1097/CCM.0B013E318165314B. View

Lin M, Weinstein R, Hota B . Delay of active antimicrobial therapy and mortality among patients with bacteremia: impact of severe neutropenia. Antimicrob Agents Chemother. 2008; 52(9):3188-94. PMC: 2533498. DOI: 10.1128/AAC.01553-07. View

Lipcsey M, Carlsson M, Larsson A, Algotsson L, Eriksson M, Lukinius A . Effect of a single dose of tobramycin on systemic inflammatory response-induced acute kidney injury in a 6-hour porcine model. Crit Care Med. 2009; 37(10):2782-90. DOI: 10.1097/CCM.0b013e3181a988f8. View

Barochia A, Cui X, Vitberg D, Suffredini A, OGrady N, Banks S . Bundled care for septic shock: an analysis of clinical trials. Crit Care Med. 2009; 38(2):668-78. PMC: 3383776. DOI: 10.1097/CCM.0b013e3181cb0ddf. View

10.

Kumar A, Safdar N, Kethireddy S, Chateau D . A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study. Crit Care Med. 2010; 38(8):1651-64. DOI: 10.1097/CCM.0b013e3181e96b91. View

11.

Kumar A, Zarychanski R, Light B, Parrillo J, Maki D, Simon D . Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med. 2010; 38(9):1773-85. DOI: 10.1097/CCM.0b013e3181eb3ccd. View

12.

Freifeld A, Bow E, Sepkowitz K, Boeckh M, Ito J, Mullen C . Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2011; 52(4):427-31. DOI: 10.1093/cid/ciq147. View

13.

Magiorakos A, Srinivasan A, Carey R, Carmeli Y, Falagas M, Giske C . Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2011; 18(3):268-81. DOI: 10.1111/j.1469-0691.2011.03570.x. View

14.

Legrand M, Max A, Peigne V, Mariotte E, Canet E, Debrumetz A . Survival in neutropenic patients with severe sepsis or septic shock. Crit Care Med. 2011; 40(1):43-9. DOI: 10.1097/CCM.0b013e31822b50c2. View

15.

Leclercq R, Canton R, Brown D, Giske C, Heisig P, MacGowan A . EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect. 2011; 19(2):141-60. DOI: 10.1111/j.1469-0691.2011.03703.x. View

16.

Baden L, Bensinger W, Angarone M, Casper C, Dubberke E, Freifeld A . Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw. 2012; 10(11):1412-45. DOI: 10.6004/jnccn.2012.0146. View

17.

Diaz-Martin A, Martinez-Gonzalez M, Ferrer R, Ortiz-Leyba C, Piacentini E, Lopez-Pueyo M . Antibiotic prescription patterns in the empiric therapy of severe sepsis: combination of antimicrobials with different mechanisms of action reduces mortality. Crit Care. 2012; 16(6):R223. PMC: 3672602. DOI: 10.1186/cc11869. View

18.

Dellinger R, Levy M, Rhodes A, Annane D, Gerlach H, Opal S . Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013; 41(2):580-637. DOI: 10.1097/CCM.0b013e31827e83af. View

19.

Azoulay E, Mokart D, Pene F, Lambert J, Kouatchet A, Mayaux J . Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium--a groupe de recherche respiratoire en réanimation onco-hématologique study. J Clin Oncol. 2013; 31(22):2810-8. DOI: 10.1200/JCO.2012.47.2365. View

20.

Paul M, Dickstein Y, Schlesinger A, Grozinsky-Glasberg S, Soares-Weiser K, Leibovici L . Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. Cochrane Database Syst Rev. 2013; (6):CD003038. PMC: 6457814. DOI: 10.1002/14651858.CD003038.pub2. View